3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
26
Neoplasm Metastasis
7
Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Advanced Solid Tumors
2
Thyroid Neoplasms
1
Recurrence Free Survival
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Histiocytosis
1
Glioma
1
Fallopian Tube Neoplasms
1
Erythema
1
Endometrial Neoplasms
1
Edema
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Colorectal Cancer Metastatic
1
Cholangiocarcinoma
1
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dihydropyrimidine Dehydrogenase Deficiency
×
Panitumumab
×
1 year
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled